Twist Bioscience SEC Filings

Twist Bioscience Corp reported a notice of proposed sale under Rule 144 for 2,517 common shares held at Fidelity Brokerage Services LLC with an aggregate market value of $82,864.17. The filing shows these shares were acquired on 10/08/2025 through restricted stock vesting and were received as compensation. The sale is scheduled to occur approximately on 10/09/2025 on NASDAQ. The filer also disclosed sales by Adam Laponis during the past three months totaling 12,242 shares for gross proceeds of $399,803.08, with individual sale dates of 07/09/2025, 08/21/2025, 10/06/2025, and 10/08/2025. Total shares outstanding are listed as 60,360,925. The notice includes the standard signer representation that no undisclosed material adverse information is known.

Twist Bioscience Corp (TWST) chief financial officer Adam Laponis sold shares to cover tax withholding tied to vested performance stock units. On 10/06/2025 the filing shows a sale of 5,875 shares at $32.187 per share as a mandatory "sell to cover" for tax obligations. After the sale the reporting person beneficially owned 97,042 shares. The form clarifies these were not discretionary trades but sales required under the company's equity plan to satisfy withholding.

Insider sale to cover tax withholding following PSU vesting. The Form 4 shows Twist Bioscience Corp (TWST) Chief Executive Officer and Director Emily M. Leproust reported a sale of 31,348 shares on 10/06/2025 at a price of $32.187 per share. The filing states the sale was a mandated "sell to cover" to satisfy tax-withholding obligations tied to vesting Performance Stock Units, not a discretionary trade. After the transaction, the Reporting Person beneficially owns 601,212 shares and holds multiple outstanding employee stock options totaling reported option counts, including 64,950 exercisable shares from a performance grant.

Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 2,041 shares of common stock on 10/06/2025 at a price of $32.187 per share. After the sale, Mr. Werner beneficially owned 46,413 shares. The filing states the shares were sold to satisfy tax-withholding obligations tied to the vesting of Performance Stock Units (PSUs) and were executed under the issuer's mandatory "sell to cover" election, not as voluntary open-market trades. The Form 4 was signed by an attorney-in-fact on 10/08/2025.

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp (TWST), reported a non‑discretionary sale of 9,724 common shares on 10/06/2025 at an effective price of $32.187 per share to satisfy tax withholding tied to vested Performance Stock Units (PSUs).

After the sell‑to‑cover, the reporting person beneficially owns 114,678 shares. The filing was submitted under Form 4 and signed by an attorney‑in‑fact on 10/08/2025. The sale was mandated by the issuer's equity plan election and is described as not a discretionary trade.

Insider sale to cover taxes: The Form 4 shows that Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), had 23,747 shares of common stock sold on 10/06/2025 at $32.187 per share. The filing states these sales were mandatory "sell to cover" transactions to meet tax‑withholding obligations tied to vested Performance Stock Units (PSUs) and were not discretionary trades. After the transaction, the reporting person beneficially owned 208,735 shares. The sale was reported on 10/08/2025 and signed by an attorney‑in‑fact.

Twist Bioscience Corp (TWST) reported an insider sale by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On 10/06/2025 Mr. Cho sold 3,876 shares of common stock at a price of $32.187 per share to satisfy tax withholding tied to the vesting of Performance Stock Units (PSUs). After the transaction he beneficially owned 98,710 shares. The filing notes these were mandatory "sell to cover" transactions elected under the company equity plans and are not discretionary trades by the reporting person.

Twist Bioscience Corp (TWST) insider filing reports a proposed sale of 3,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $93,450, and an approximate sale date of 10/08/2025 on NASDAQ. The shares were acquired on 10/01/2025 via restricted stock vesting and were paid as compensation. The filer also disclosed three prior open-market sales during the past three months totaling 9,242 shares for gross proceeds of $306,353.08 (sales on 07/09/2025, 08/21/2025, and 10/06/2025). The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.

Artisan Partners group reported beneficial ownership of 6,410,900 shares of Twist Bioscience Corporation common stock, representing 10.6% of the outstanding class based on 07/30/2025 share count. The filing shows no sole voting or dispositive power; instead the filers report shared voting power of 5,303,412 shares and shared dispositive power of 6,410,900. The shares are held for discretionary clients of Artisan Partners Limited Partnership and, according to the certification, were acquired in the ordinary course of business and not with the purpose of changing control. The report is filed as a joint Schedule 13G amendment and includes a joint filing agreement signed on 10/07/2025.